Abera Bioscience AB
Company Showcase Sponsor
Abera Bioscience is a biotechnology company developing next-generation mucosal vaccines to prevent serious infectious diseases. Our vaccine candidates are based on a versatile proprietary platform using outer membrane vesicles (OMVs) decorated with disease-specific antigens, enabling strong and broad immune responses. By targeting the mucosal immune system through intranasal administration, Abera’s technology has the potential to provide both local and systemic protection while helping to reduce transmission. Our lead candidate is a serotype-independent pneumococcal vaccine entering Phase 1 in 2026. In parallel, Abera is actively engaged in pandemic preparedness, including development of a nasal influenza vaccine designed for rapid adaptation.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events